215 related articles for article (PubMed ID: 34862242)
1. Modulation of the Human Pancreatic Ductal Adenocarcinoma Immune Microenvironment by Stereotactic Body Radiotherapy.
Mills BN; Qiu H; Drage MG; Chen C; Mathew JS; Garrett-Larsen J; Ye J; Uccello TP; Murphy JD; Belt BA; Lord EM; Katz AW; Linehan DC; Gerber SA
Clin Cancer Res; 2022 Jan; 28(1):150-162. PubMed ID: 34862242
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
3. CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.
Ye J; Gavras NW; Keeley DC; Hughson AL; Hannon G; Vrooman TG; Lesch ML; Johnston CJ; Lord EM; Belt BA; Linehan DC; Eyles J; Gerber SA
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37142292
[TBL] [Abstract][Full Text] [Related]
4. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET.
Toesca DAS; Pollom EL; Poullos PD; Flynt L; Cui Y; Quon A; von Eyben R; Koong AC; Chang DT
Pract Radiat Oncol; 2017; 7(2):120-125. PubMed ID: 28274396
[TBL] [Abstract][Full Text] [Related]
5. A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE).
van Goor IWJM; Daamen LA; Besselink MG; Bruynzeel AME; Busch OR; Cirkel GA; Groot Koerkamp B; Haj Mohammed N; Heerkens HD; van Laarhoven HWM; Meijer GJ; Nuyttens J; van Santvoort HC; van Tienhoven G; Verkooijen HM; Wilmink JW; Molenaar IQ; Intven MPW;
Trials; 2022 Oct; 23(1):913. PubMed ID: 36307892
[TBL] [Abstract][Full Text] [Related]
6. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
7. Pain Relief after Stereotactic Radiotherapy of Pancreatic Adenocarcinoma: An Updated Systematic Review.
Buwenge M; Arcelli A; Cellini F; Deodato F; Macchia G; Cilla S; Galietta E; Strigari L; Malizia C; Cammelli S; Morganti AG
Curr Oncol; 2022 Apr; 29(4):2616-2629. PubMed ID: 35448188
[TBL] [Abstract][Full Text] [Related]
8. Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma.
Simoni N; Micera R; Paiella S; Guariglia S; Zivelonghi E; Malleo G; Rossi G; Addari L; Giuliani T; Pollini T; Cavedon C; Salvia R; Milella M; Bassi C; Mazzarotto R
Clin Oncol (R Coll Radiol); 2021 Jan; 33(1):e31-e38. PubMed ID: 32682686
[TBL] [Abstract][Full Text] [Related]
9. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC).
Pavic M; Niyazi M; Wilke L; Corradini S; Vornhülz M; Mansmann U; Al Tawil A; Fritsch R; Hörner-Rieber J; Debus J; Guckenberger M; Belka C; Mayerle J; Beyer G
Radiat Oncol; 2022 Jan; 17(1):18. PubMed ID: 35078490
[TBL] [Abstract][Full Text] [Related]
10. Radiotherapy for locally advanced pancreatic ductal adenocarcinoma.
Buss EJ; Kachnic LA; Horowitz DP
Semin Oncol; 2021 Feb; 48(1):106-110. PubMed ID: 33771355
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy in pancreatic adenocarcinoma.
de la Pinta C
Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):14-19. PubMed ID: 36990839
[TBL] [Abstract][Full Text] [Related]
12. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review.
Vornhülz M; Anton S; Eross B; Szakács Z; Hegyi P; Regel I; Belka C; Niyazi M; Mayerle J; Beyer G
Radiat Oncol; 2022 Jun; 17(1):108. PubMed ID: 35715808
[TBL] [Abstract][Full Text] [Related]
13. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
[TBL] [Abstract][Full Text] [Related]
14. Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer.
Mokhtech M; Miccio JA; Johung K; Cecchini M; Stein S; Narang AK; Herman JM; Kunstman J; Haddock MG; Anker CJ; Jabbour S; Hallemeier CL; Jethwa KR
Am J Clin Oncol; 2022 Nov; 45(11):450-457. PubMed ID: 36318696
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Xie C; Duffy AG; Brar G; Fioravanti S; Mabry-Hrones D; Walker M; Bonilla CM; Wood BJ; Citrin DE; Gil Ramirez EM; Escorcia FE; Redd B; Hernandez JM; Davis JL; Gasmi B; Kleiner D; Steinberg SM; Jones JC; Greten TF
Clin Cancer Res; 2020 May; 26(10):2318-2326. PubMed ID: 31996388
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.
Mills BN; Connolly KA; Ye J; Murphy JD; Uccello TP; Han BJ; Zhao T; Drage MG; Murthy A; Qiu H; Patel A; Figueroa NM; Johnston CJ; Prieto PA; Egilmez NK; Belt BA; Lord EM; Linehan DC; Gerber SA
Cell Rep; 2019 Oct; 29(2):406-421.e5. PubMed ID: 31597100
[TBL] [Abstract][Full Text] [Related]
17. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
18. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.
Ye J; Mills BN; Zhao T; Han BJ; Murphy JD; Patel AP; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
Cancer Immunol Res; 2020 Jan; 8(1):94-107. PubMed ID: 31719057
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
20. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]